Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization
Journal of Circulating Biomarkers · 02.11.2015 · 4 · 3
DOI: 10.5772/60725 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Circulating Biomarkers, online erschienen am 30.01.2015. Verfasst von Shannon L Werner und 8 weiteren Autor:innen. Beteiligte Einrichtung: Epic Sciences, Inc., San Diego, CA, USA. Die Arbeit wurde bisher 108-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The Epic Platform was developed for the unbiased detection and molecular characterization of circulating tumour cells (CTCs). Here, we report assay performance data, including accuracy, linearity, specificity and intra/inter-assay precision of CTC enumeration in healthy donor (HD) blood samples spiked with varying concentrations of cancer cell line controls (CLCs). Additionally, we demonstrate clinical feasibility for CTC detection in a small cohort of metastatic castrate-resistant prostate cancer (mCRPC) patients. The Epic Platform demonstrated accuracy, linearity and sensitivity for the enumeration of all CLC concentrations tested. Furthermore, we established the precision between multiple operators and slide staining batches and assay specificity showing zero CTCs detected in 18 healthy donor samples. In a clinical feasibility study, at least one traditional CTC/mL (CK+, CD45-, and intact nuclei) was detected in 89 % of 44 mCRPC samples, whereas 100 % of samples had CTCs enumerated if additional CTC subpopulations (CK-/CD45- and CK+ apoptotic CTCs) were included in the analysis. In addition to presenting Epic Platform's performance with respect to CTC enumeration, we provide examples of its integrated downstream capabilities, including protein biomarker expression and downstream genomic analyses at single cell resolution.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Epic Sciences, Inc., San Diego, CA, USA.
Zitieren
APA
Werner, S. L., Graf, R. P., Landers, M., Valenta, D. T., Schroeder, M., Greene, S. B., Bales, N., Dittamore, R., & Marrinucci, D. (2015). Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization. Journal of Circulating Biomarkers, 4, 3. https://doi.org/10.5772/60725
Vancouver
Werner SL, Graf RP, Landers M, Valenta DT, Schroeder M, Greene SB, et al. Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization. Journal of Circulating Biomarkers. 2015;4:3. doi:10.5772/60725
BibTeX
@article{Werner2015,
author = {Werner, Shannon L and Graf, Ryon P and Landers, Mark and Valenta, David T and Schroeder, Matthew and Greene, Stephanie B and Bales, Natalee and Dittamore, Ryan and Marrinucci, Dena},
title = {Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization},
journal = {Journal of Circulating Biomarkers},
year = {2015},
volume = {4},
pages = {3},
doi = {10.5772/60725}
}
EUVIMED